Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor

Affiliations

¹ Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. jose.silva@mssm.edu.
² Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
³ Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

Comment

Jose Silva et al. Nat Cancer. 2023 Jun.

. 2023 Jun;4(6):809-811.

doi: 10.1038/s43018-023-00583-2. Epub 2023 Jun 15.

¹ Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. jose.silva@mssm.edu.
² Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
³ Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

No abstract available

Comment on

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, Accordino M, Crew KD, Hershman DL, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Zeleke TZ, et al. Nat Cancer. 2023 Feb;4(2):257-275. doi: 10.1038/s43018-022-00489-5. Epub 2022 Dec 30. Nat Cancer. 2023. PMID: 36585452 Free PMC article.
Ricolinostat is not a highly selective HDAC6 inhibitor.
Médard G, Sheltzer JM. Médard G, et al. Nat Cancer. 2023 Jun;4(6):807-808. doi: 10.1038/s43018-023-00582-3. Epub 2023 Jun 15. Nat Cancer. 2023. PMID: 37322365 No abstract available.

1. Visvader, J. E. & Lindeman, G. J. Mammary stem cells and mammopoiesis. Cancer Res. 66, 9798–9801 (2006). - DOI - PubMed
1. Depetter, Y. et al. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int. J. Cancer 145, 735–747 (2019). - DOI - PubMed
1. Winkler, R. et al. Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. Oncogene 41, 4560–4572 (2022). - DOI - PubMed - PMC
1. Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11, eaaw8412 (2019).
1. Teng, X. et al. Genome-wide consequences of deleting any single gene. Mol. Cell 52, 485–494 (2013). - DOI - PubMed - PMC